Profile data is unavailable for this security.
About the company
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
- Revenue in USD (TTM)71.55m
- Net income in USD-81.10m
- Incorporated2014
- Employees786.00
- LocationBurning Rock Biotech LtdNo. 5 Xingdao Ring Road NorthInternational Bio IslandGUANGZHOU 510005ChinaCHN
- Phone+86 18 501641666
- Websitehttps://www.brbiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nutex Health Inc | 258.77m | -41.00m | 37.34m | 800.00 | -- | 0.5925 | -- | 0.1443 | -9.18 | -9.18 | 57.05 | 12.67 | 0.6203 | 67.70 | 4.41 | 323,463.30 | -8.88 | -69.35 | -10.70 | -84.85 | 15.49 | 10.97 | -14.32 | -102.85 | 1.63 | 0.2489 | 0.7617 | -- | 12.93 | 428.22 | 89.22 | -- | -- | -- |
| Oncology Institute Inc | 342.71m | -59.65m | 40.94m | 800.00 | -- | 0.9897 | -- | 0.1195 | -0.8066 | -0.8066 | 4.63 | 0.5557 | 1.56 | 26.16 | 6.55 | 428,391.30 | -33.23 | -- | -40.16 | -- | 16.76 | 19.54 | -21.29 | -9.99 | 2.83 | -7.94 | 0.6816 | -- | 28.42 | 23.43 | -99,919.12 | -- | 45.68 | -- |
| Inspire Veterinary Partners Inc | 17.22m | -17.16m | 55.66m | 156.00 | -- | 88.10 | -- | 3.23 | -145.00 | -145.00 | 6.65 | 0.0582 | 0.7929 | 23.84 | 83.61 | 110,413.10 | -76.76 | -- | -125.02 | -- | 20.70 | -- | -96.81 | -- | 0.3069 | -3.25 | 0.9848 | -- | 69.56 | -- | -206.68 | -- | -- | -- |
| ProPhase Labs Inc | 28.72m | -23.60m | 59.72m | 113.00 | -- | 1.26 | -- | 2.08 | -1.34 | -1.34 | 1.64 | 2.49 | 0.3098 | 5.81 | 0.7872 | 254,115.00 | -25.45 | 0.9106 | -33.00 | 1.12 | 18.41 | 50.32 | -82.18 | 0.9325 | 1.73 | -20.42 | 0.1953 | 665.78 | -63.81 | 27.59 | -190.90 | -- | 86.46 | -- |
| CRYO-CELL International, Inc. | 31.64m | -9.30m | 62.40m | 82.00 | -- | -- | -- | 1.97 | -1.12 | -1.12 | 3.81 | -1.33 | 0.4819 | 10.60 | 4.68 | 385,873.80 | -14.16 | 0.4686 | -20.18 | 0.7099 | 73.40 | 70.09 | -29.38 | 0.8133 | 0.4858 | -- | -- | -- | 3.32 | 1.41 | -443.57 | -- | 60.30 | -- |
| Burning Rock Biotech Ltd (ADR) | 71.55m | -81.10m | 69.76m | 786.00 | -- | 0.7069 | -- | 0.9749 | -64.52 | -64.52 | 21.48 | 9.62 | 0.4334 | 1.93 | 3.13 | 91,035.79 | -49.12 | -37.09 | -65.97 | -45.29 | 67.27 | 70.02 | -113.34 | -123.88 | 3.05 | -- | 0.00 | -- | -4.58 | 20.81 | 32.69 | -- | -17.61 | -- |
| American Oncology Network Inc | 1.34bn | -15.48m | 75.38m | 1.53k | -- | -- | -- | 0.0563 | -2.07 | -2.07 | 161.04 | -9.94 | 3.53 | 33.53 | 9.26 | 878,552.80 | -22.82 | -- | -78.96 | -- | 5.00 | -- | -6.46 | -- | 1.20 | -7.84 | 0.606 | -- | 11.27 | -- | -- | -- | -- | -- |
| Cardiff Lexington Corp | 11.65m | 2.36m | 91.14m | 10.00 | 0.4311 | -- | 38.23 | 7.82 | 16.24 | 11.60 | 10.18 | 0.6702 | 0.6319 | -- | 1.05 | 1,165,444.00 | 16.04 | -- | 52.14 | -- | 69.75 | 62.01 | 25.39 | -- | -- | 2.66 | 0.5106 | -- | -- | 39.71 | -- | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Kynam Capital Management LPas of 31 Mar 2024 | 964.09k | 11.71% |
| Massachusetts Financial Services Co.as of 31 Mar 2024 | 402.69k | 4.89% |
| MFS International (UK) Ltd.as of 31 May 2024 | 330.77k | 4.02% |
| FIL Investment Advisors (UK) Ltd.as of 31 Mar 2024 | 280.90k | 3.41% |
| Millennium Management LLCas of 31 Mar 2024 | 173.72k | 2.11% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2024 | 59.14k | 0.72% |
| Nikko Asset Management Co., Ltd.as of 30 Jun 2024 | 56.25k | 0.68% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 34.27k | 0.42% |
| MFS International Singapore Pte Ltd.as of 31 May 2024 | 32.80k | 0.40% |
| BofA Securities, Inc.as of 31 Mar 2024 | 29.17k | 0.35% |
